AFP and hepatocellular carcinoma: Treatment of HCC patients undergoing liver transplantation with mTOR-inhibitor temsirolimus for ≥3 months improved survival outcomes, and the greatest benefit was observed in the subgroup with AFP ≥10 ng/ml (118).